Warner Chilcott Hits Watson With Atelvia Patent Suit

Law360, New York (October 18, 2011, 6:49 PM EDT) -- Watson Pharmaceuticals Inc. confirmed Monday that Warner Chilcott LLC has launched a patent suit in New Jersey seeking to stop the company from marketing a generic version of the postmenopausal osteoporosis drug Atelvia.

Ireland-based Warner Chilcott and its New Jersey subsidiary, Warner Chilcott Co. LLC, filed suit on Oct. 12, accusing Watson of infringing U.S. Patent Numbers 7,645,459 and 7,645,460, which cover “Dosage Forms of Bisphosphonates” and “Dosage Forms of Risedronate,” the active ingredient in Atelvia.

Warner Chilcott's patents were issued in January 2010 and the...
To view the full article, register now.